Metabolic syndrome and esophageal and gastric cancer

被引:48
|
作者
Lin, Yulan [1 ,2 ]
Ness-Jensen, Eivind [1 ,3 ]
Hveem, Kristian [3 ]
Lagergren, Jesper [1 ,4 ]
Lu, Yunxia [1 ,5 ]
机构
[1] Karolinska Inst, Dept Mol Med & Surg, Upper Gastrointestinal Surg, S-17176 Stockholm, Sweden
[2] Norwegian Univ Sci & Technol, European Palliat Care Res Ctr, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway
[3] Norwegian Univ Sci & Technol, HUNT Res Ctr, Dept Publ Hlth & Gen Practice, Levanger, Norway
[4] Kings Coll London, Div Canc Studies, London WC2R 2LS, England
[5] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London, England
基金
瑞典研究理事会;
关键词
Serum lipid; Metabolic syndrome; Hypertension; Neoplasm; Esophagus; Stomach; PROJECT ME-CAN; PROSPECTIVE COHORT; RISK-FACTORS; OBESITY; ADENOCARCINOMA; PREVALENCE; NORWAY; ATHEROSCLEROSIS; CARCINOMA; PRESSURE;
D O I
10.1007/s10552-015-0675-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of the metabolic syndrome in the etiology of esophageal and gastric cancer is unclear. This was a large nationwide cohort study based on data from 11 prospective population-based cohorts in Norway with long-term follow-up, the Cohort of Norway (CONOR) and the third Nord-Trondelag Health Study (HUNT3). The metabolic syndrome was assessed by objective anthropometric and metabolic biochemical measures and was defined by the presence of at least three of the following five factors: increased waist circumference, elevated triglycerides, low high-density lipoprotein cholesterol, hypertension and high glucose. Newly diagnosed cases of esophageal adenocarcinoma, esophageal squamous-cell carcinoma and gastric adenocarcinoma were identified from the Norwegian Cancer Registry. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard models with adjustment for potential confounders. Among 192,903 participants followed up for an average of 10.6 years, 62 developed esophageal adenocarcinoma, 64 had esophageal squamous-cell carcinoma and 373 had gastric adenocarcinoma. The metabolic syndrome was significantly associated with an increased risk of gastric adenocarcinoma (HR 1.44, 95 % CI 1.14-1.82), but not associated with esophageal adenocarcinoma (HR 1.32, 95 % CI 0.77-2.26) or esophageal squamous-cell carcinoma (HR 1.08, 95 % CI 0.64-1.83). Increased waist circumference was associated with an increased HR of esophageal adenocarcinoma (HR 2.48, 95 % CI 1.27-4.85). No significant association was found between any single component of the metabolic syndrome and risk of esophageal squamous-cell carcinoma. High waist circumference (HR 1.71, 95 % CI 1.05-2.80), hypertension (HR 2.41, 95 % CI 1.44-4.03) and non-fasting glucose (HR 1.74, 95 % CI 1.18-2.56) were also related to an increased risk of gastric adenocarcinoma in women, but not in men. Metabolic syndrome was associated with an increased risk of gastric adenocarcinoma in women. Of the individual components of the metabolic syndrome, high waist circumference was positively associated with risk of esophageal adenocarcinoma. Positive associations were also observed for women between high waist circumference, hypertension, high non-fasting glucose and risk of gastric adenocarcinoma. However, further evidence is warranted due to the limited number of cases and the inability to effectively identify gastric cardia adenocarcinoma.
引用
收藏
页码:1825 / 1834
页数:10
相关论文
共 50 条
  • [41] Analysis of metabolic characteristics of metabolic syndrome in elderly patients with gastric cancer by non-targeted metabolomics
    Zhang, Huan
    Shen, Wen-Bing
    Chen, Lin
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (06) : 2419 - 2428
  • [42] Update ESMO: gastric and esophageal cancer
    Ulrich Popper
    Holger Rumpold
    memo - Magazine of European Medical Oncology, 2021, 14 : 180 - 183
  • [43] POLYAMINES IN HUMAN GASTRIC AND ESOPHAGEAL CANCER
    LOSER, C
    FOLSCH, UR
    PAPROTNY, C
    CREUTZFELDT, W
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 (10) : 1193 - 1199
  • [44] Cholecystectomy and the risk of esophageal and gastric cancer
    Ge, Zhenming
    Zhao, Chengjin
    Wang, Yamin
    Qian, Junbo
    SAUDI MEDICAL JOURNAL, 2012, 33 (10) : 1073 - 1079
  • [45] Multidisciplinary management for esophageal and gastric cancer
    Boniface, Megan M.
    Wani, Sachin B.
    Schefter, Tracey E.
    Koo, Phillip J.
    Meguid, Cheryl
    Leong, Stephen
    Kaplan, Jeffrey B.
    Wingrove, Lisa J.
    McCarter, Martin D.
    CANCER MANAGEMENT AND RESEARCH, 2016, 8 : 39 - 44
  • [46] Developments in Treatment of Esophageal/Gastric Cancer
    Liu, Wei
    Zhang, Xiaodong
    Sun, Weijing
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2008, 9 (4-6) : 375 - 387
  • [47] Update ESMO: gastric and esophageal cancer
    Popper, Ulrich
    Rumpold, Holger
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (02) : 180 - 183
  • [48] Metabolic Reprogramming of Gastric Cancer
    Li Bin Sun
    Wen Sheng Qiu
    Jing Guo
    Journal of Nutritional Oncology, 2018, 3 (01) : 19 - 24
  • [49] Immunological and Metabolic Alterations in Esophageal Cancer
    Mikhael, Mary
    Pasha, Bilal
    Chela, Harleen
    Tahan, Veysel
    Daglilar, Ebubekir
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2022, 22 (06) : 579 - 589
  • [50] Esophageal Tumor After Radical Surgery for Gastric Cancer Solitary Esophageal Metastasis Arising From Gastric Cancer
    Namikawa, Tsutomu
    Kobayashi, Michiya
    Hanazaki, Kazuhiro
    GASTROENTEROLOGY, 2015, 148 (04) : E9 - E10